Comparison of Local Anesthetic Infiltration and Different Fascial Plane Blocks in Inguinal Hernia Repair
Launched by ESKISEHIR OSMANGAZI UNIVERSITY · May 4, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying different methods of pain management for patients undergoing surgery to repair an inguinal hernia, which is a common condition where tissue pushes through a weak spot in the abdominal muscles. The researchers are comparing three techniques: a local anesthetic injection directly into the surgery area, a quadratus lumborum block (QLB), and a transversus abdominis plane block (TAP). These methods will help reduce pain after surgery and improve the overall recovery experience for patients.
To participate in this trial, you need to be between the ages of 18 and 80 and scheduled for an elective surgery to repair a unilateral inguinal hernia using general anesthesia. You should generally be in good health according to the American Society of Anesthesiology's classification, which means you can have mild to moderate health conditions but not severe ones. If you have had previous hernia surgery, are taking certain blood-thinning medications, or have issues that make communication difficult, you may not be eligible. Participants will receive one of the pain management techniques before their surgery and will be monitored for pain levels and recovery quality afterward. This study aims to find the most effective way to manage pain after hernia repair surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who will undergo elective unilateral inguinal herniorrhaphy under general anesthesia
- • American Society of Anesthesiology (ASA) physical classification I-III
- Exclusion Criteria:
- • Patients who will undergo laparoscopic surgery
- • Previous inguinal hernia repair surgery
- • A history of opioid use or pain management
- • Coagulopathy or anticoagulant use
- • Patients who have difficulty communicating or who are not cooperative
About Eskisehir Osmangazi University
Eskisehir Osmangazi University is a distinguished academic institution dedicated to advancing medical research and education. With a commitment to enhancing healthcare outcomes, the university actively sponsors clinical trials that explore innovative therapeutic approaches and contribute to the scientific community. Leveraging its state-of-the-art facilities and a team of experienced researchers, Eskisehir Osmangazi University fosters collaboration across disciplines to address pressing health challenges and improve patient care. Through its rigorous research initiatives, the university aims to translate findings into practical applications that benefit both local and global populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Eskisehir, , Turkey
Eskişehir, , Turkey
Patients applied
Trial Officials
Gulay Erdogan Kayhan, Prof Dr
Principal Investigator
Eskisehir Osmangazi University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported